Publications by authors named "Auma Betty"

Claim this Profile
P
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
Jennifer Serwanga, Gerald Kevin Oluka, Claire Baine, Violet Ankunda, Jackson Sembera, Betty Oliver Auma

PLoS One· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
Ivan Ssali, Susan Mugaba, Arthur Kalyebi Watelo, Juliana Bemanzi, Joseph Ssebwana Katende, Betty Oliver Auma

Int J Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.
Jennifer Serwanga, Claire Baine, Susan Mugaba, Violet Ankunda, Betty Oliver Auma

Front Immunol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
Jennifer Serwanga, Violet Ankunda, Jackson Sembera, Laban Kato, Gerald Kevin Oluka, Betty Oliver Auma

Front Immunol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.
Ritah Nakiboneka, Susan Mugaba, Betty O Auma, Christopher Kintu, Christina Lindan

Vaccine· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.
Jennifer Serwanga, Susan Mugaba, Auma Betty, Edward Pimego, Sarah Walker

AIDS Res Treat· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans.
Jennifer Serwanga, Leigh Anne Shafer, Edward Pimego, Betty Auma, Christine Watera

PLoS One· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV type 1-specific inter- and intrasubtype cellular immune responses in HIV type 1-infected Ugandans.
Alleluiah Rutebemberwa, Betty Auma, Jill Gilmour, Gareth Jones, David Yirrell

AIDS Res Hum Retroviruses· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis